Kyowa Kirin initiates first-in-human trial for KK2223 in T Cell Non-Hodgkin Lymphoma
Kyowa Kirin is conducting a first-in-human study to evaluate KK2223 in patients with relapsed or refractory T cell lymphoma.
Asset / Drug
Drug and asset intelligence for KK2223 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.